Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis

Lancet Child Adolesc Health. 2024 Oct;8(10):708-709. doi: 10.1016/S2352-4642(24)00228-1. Epub 2024 Aug 26.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antiviral Agents / therapeutic use
  • Bronchiolitis / drug therapy
  • Bronchiolitis, Viral / drug therapy
  • Humans
  • Infant
  • Palivizumab / therapeutic use
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus, Human

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab